Business
Tetra Bio-Pharma Provides Management Update on Tetra Natural Health’s Commercial Activities
Tetra Bio-Pharma Provides Management Update on Tetra Natural Health’s Commercial Activities.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n Azevedos To Commercialize Awaye™ in Portugal, Tunisia and Mozambique in Q1 2020 Tetra to submit two non-prescription DIN applications in Canada Tetra to commercialize non-prescription drugs in USA OTTAWA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Tetra Natural Health (“TNH”) a wholly owned subsidiary of Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF) is pleased to provide an update on its initiatives to bring its Awaye™ topical product for pain relief to the market globally and its activities to commercialize additional natural health products and non-prescription drugs in Canada and the USA. TNH is focused on entering into distribution partnerships for the commercialization of its OTC (Over-The-Counter) pain medications in the US$ 19 billion dollar market, which is expected to see steady growth according, to Future Market Insights.  The portfolio of OTC drug products that Tetra is preparing to commercialize are at an advanced stage (i.e., DIN submission). There are no further required capital investment or additional clinical research necessary to bring these products to market.  Tetra to submit its first two non-prescription DIN applications in Canada Tetra confirms that it has completed the development of two OTC DIN products; one for the treatment of hemorrhoids and the other for the temporary relief of aches and pains of muscles and joints associated with backache, lumbago, strains, bruises, sprains and arthritic or rheumatic pain, pain of tendons and ligaments.  The non-prescription drug applications are completed and will be submitted to Health Canada before the end of Tetra’s fiscal year ending November 30th, 2019. Tetra also plans to release these products in USA market in 2020. In preparation for its 2020 product launch, Tetra is in contact with a contract manufacturer to set up the manufacturing and to obtain a National Drug Code (NDC) number from the U.S. Food and Drug Administration (FDA) for each drug. An NDC number is required for all OTC drugs sold in the USA. Tetra has developed several other non-prescription drug products for the Canadian and USA Over-the-Counter (OTC) drug markets.  This OTC drug product line will contain beta-caryophyllene and will not require any clinical trial data to support its DIN appli...